Christou, GA, Katsiki, N, Blundell, J orcid.org/0000-0002-7085-9596 et al. (2 more authors) (2019) Semaglutide as a promising antiobesity drug. Obesity Reviews, 20 (6). pp. 805-815. ISSN 1467-7881
Abstract
Semaglutide is a glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) with a long elimination half‐life, allowing subcutaneous (sc) administration once per week. Both the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) recently approved once‐weekly sc semaglutide for the treatment of type 2 diabetes mellitus (T2DM). The weight loss efficacy of once‐weekly sc semaglutide appears to be superior compared with the other once‐weekly GLP‐1 RAs in patients with T2DM. Semaglutide was recently evaluated as an antiobesity drug in a phase II dose‐finding trial, which demonstrated superior weight loss efficacy of once daily sc semaglutide compared with both placebo and once daily 3.0 mg liraglutide in patients with obesity but without T2DM. The magnitude of semaglutide‐induced weight loss in this study exceeded the criteria of both the EMA and FDA for antiobesity drugs, and there were no safety concerns, indicating the eligibility of once daily sc semaglutide as a future antiobesity drug.
Metadata
Item Type: | Article |
---|---|
Authors/Creators: |
|
Keywords: | glucagon‐like peptide‐1 receptor agonist; obesity; semaglutide; weight loss |
Dates: |
|
Institution: | The University of Leeds |
Academic Units: | The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Psychology (Leeds) |
Depositing User: | Symplectic Publications |
Date Deposited: | 20 Jun 2019 11:40 |
Last Modified: | 20 Jun 2019 11:40 |
Status: | Published |
Publisher: | Wiley |
Identification Number: | 10.1111/obr.12839 |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:147558 |